Trial · NCT02771977
Drug-Targeted Alerts for Acute Kidney Injury
NCT02771977, Not applicable, Completed, Yale University; results first posted 2023-06-29
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. Drug-Targeted Alerts for Acute Kidney Injury. Trials, record NCT02771977. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02771977
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Drug-Targeted Alerts for Acute Kidney Injury
- NCT number
- NCT02771977
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 5,060 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Acute Kidney Injury
- Interventions
- Drug-specific alert
- First posted
- 2016-05-13
- Last updated
- 2024-02-15
- Results first posted
- 2023-06-29
- Limitations and caveats
Limitations include the fact that only three medication classes were targeted, that this trial was randomized at the patient level, which introduces the possibility of contamination, that it was conducted within a single health system, potentially limiting generalizability, that alert fatigue may have diminished alert performance as it was displayed in competition with all other alerts, and that the language of the alert was limited in how stringently it could recommend medication cessation.
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Progression of AKI OR Dialysis OR Death | 14 days from Randomization | Progression of AKI is defined by an increase in KDIGO creatinine stage from time of randomization to the present. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital records. |
| Secondary | Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Assessed within 24 hours from randomization | The Percentage of patients for whom the targeted agent was discontinued within 24 hours from randomization. For individuals with active orders for more than one targeted agent, cessation of any will be adequate to meet this endpoint. |
| Secondary | 14- Day Mortality Rate | Assessed from date of randomization to date of death from any cause, within 14 days of randomization | Percentage of patients who expire within 14 days of randomization |
| Secondary | Inpatient Mortality Rate | Assessed from point of randomization to the date of death from any cause during the end of current index hospitalization, up to 365 days | Percentage of patients who expire during index hospitalization. |
| Secondary | Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization | Receipt of hemodialysis, continuous renal replacement, or peritoneal dialysis within 14 days of randomization |
| Secondary | Percentage of Patients on Inpatient Dialysis | Assessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 365 days | Receipt of hemodialysis, continuous renal replacement, or peritoneal dialysis during index hospitalization |
| Secondary | Percentage of Patients Discharged on Dialysis | Assessed at the point of discharge from index hospitalization, up to 365 days post randomization | Active orders for dialysis at the point of discharge from the index hospitalization |
| Secondary | Percentage of Patients With AKI Progression From Stage 1 to Stage 2 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Progression to stage 2 AKI, represented by a doubling of baseline creatinine levels. |
| Secondary | Percentage of Patients With AKI Progression From Stage 2 to Stage 3 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Progression to stage 3 AKI, represented by a tripling of baseline creatinine levels. |
| Secondary | AKI Duration | Assessed from the point of randomization to the point of AKI cessation during index hospitalization, up to 365 days | Time in hours between AKI onset and AKI cessation during index hospitalization |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Progression of AKI OR Dialysis OR Death | 14 days from Randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Assessed within 24 hours from randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | 14- Day Mortality Rate | Assessed from date of randomization to date of death from any cause, within 14 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Inpatient Mortality Rate | Assessed from point of randomization to the date of death from any cause during the end of current index hospitalization, up to 365 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on Inpatient Dialysis | Assessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 365 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients Discharged on Dialysis | Assessed at the point of discharge from index hospitalization, up to 365 days post randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients With AKI Progression From Stage 1 to Stage 2 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Population analyzed represents the number of subjects with AKI Stage 1 upon enrollment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Patients With AKI Progression From Stage 2 to Stage 3 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Analyzed population includes subjects with Stage 1 or Stage 2 AKI upon enrollment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | AKI Duration | Assessed from the point of randomization to the point of AKI cessation during index hospitalization, up to 365 days | days | MEDIAN |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Progression of AKI OR Dialysis OR Death | Usual Care | 639 | Participants | ||
| Percentage of Patients With Progression of AKI OR Dialysis OR Death | Drug-specific Alert | 585 | Participants | ||
| Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Usual Care | 1413 | Participants | ||
| Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Drug-specific Alert | 1547 | Participants | ||
| 14- Day Mortality Rate | Usual Care | 282 | Participants | ||
| 14- Day Mortality Rate | Drug-specific Alert | 253 | Participants | ||
| Inpatient Mortality Rate | Usual Care | 365 | Participants | ||
| Inpatient Mortality Rate | Drug-specific Alert | 356 | Participants | ||
| Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Usual Care | 127 | Participants | ||
| Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Drug-specific Alert | 123 | Participants |
1 to 10 of 46Source ClinicalTrials.gov
See all 46 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Usual Care | 2,528 | |
| Overall Study | STARTED | Drug-specific Alert | 2,532 | |
| Overall Study | COMPLETED | Usual Care | 2,528 | |
| Overall Study | COMPLETED | Drug-specific Alert | 2,532 | |
| Overall Study | NOT COMPLETED | Usual Care | 0 | |
| Overall Study | NOT COMPLETED | Drug-specific Alert | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Usual Care | 365 | 2,528 |
| Total, all-cause mortality | Drug-specific Alert | 356 | 2,532 |
| Total, other adverse events | Usual Care | 0 | 2,528 |
| Total, other adverse events | Drug-specific Alert | 0 | 2,532 |
| Total, serious adverse events | Usual Care | 0 | 2,528 |
| Total, serious adverse events | Drug-specific Alert | 0 | 2,532 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK113191 | Optimizing Electronic Alerts for Acute Kidney Injury | WILSON, FRANCIS PERRY | YALE UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2018 to 2022 |
Source NIH RePORTER
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Drug-specific Alert vs Usual Care: Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Subjects With Chart Documentation of AKI | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Patients With Progression of AKI OR Dialysis OR Death | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Patients Discharged on Dialysis | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Patients With AKI Progression From Stage 1 to Stage 2 | Trial comparisons |
| Drug-specific Alert vs Usual Care: Readmission Rate | Trial comparisons |
| Drug-specific Alert vs Usual Care: Percentage of Patients on Inpatient Dialysis | Trial comparisons |
| Drug-specific Alert vs Usual Care: 14- Day Mortality Rate | Trial comparisons |
| Drug-specific Alert vs Usual Care: deaths from any cause | Trial comparisons |
1 to 10 of 13
See all 13 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02771977
GET https://conductscience.org/api/trials/v1/NCT02771977/results?page=2